Side effects of systemic cyclosporine in patients not undergoing transplantation

      This paper is only available as a PDF. To read, Please Download here.


      Twenty-six patients with ocular inflammatory disorders of presumed autoimmune origin were treated with oral cyclosporine. Cyclosporine is a potent T cell regulatory agent that has been utilized extensively in organ transplantation. In general, the patients in this study did not have chronic debilitating illnesses that are observed in organ transplant recipients, did not receive corticosterolds in addition to cyclosporine, and did not undergo any surgical procedure during their treatment. This study describes the observed adverse reactions in this group of patients not undergoing transplantation. The reported side effects of cyclosporine in organ transplant recipients have included nephrotoxicity, hepatotoxicity, infections, lymphoma, hirsutism, gingivitis, and central nervous system toxicity. Side effects were observed that were similar to those in previous reports, but the severity of the nephrotoxicity and hepatotoxicity appeared to be less. Nephrotoxicity occurred in eight patients and hepatotoxicity occurred in one patient. No lymphomas were seen. Hypertension and anemia each were observed in six patients. In addition, previously unreported effects of hyperuricemia, elevated sedimentation rate, and hidradenits were observed. However, the overall severity of the side effects did not seriously affect the usage of cyclosporine in the patients in this study. Cyclosporine may be useful in the treatment of other autoimmune diseases.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Borel JF
        • Lafferty KJ
        Cyclosporine: speculation about its mechanism of action.
        Transplant Proc. 1983; 15: 1881-1885
        • Starzl TE
        • Iwatsuki S
        • Bahnson HB
        • et al.
        Cyclosporin A and steroids for liver and heart transplantation.
        in: White DJG Cyclosporin A. Elsevier Biomedical Press, Amsterdam, The Netherlands1982: 431-436
        • Nussenblatt RB
        • Palestine AG
        • Rook AH
        • Scher I
        • Wacker WB
        • Gery I
        Treatment of intraocular inflammatory disease with cyclosporin A.
        Lancet. 1983; II: 235-238
        • Nussenblatt RB
        • Palestine AG
        • Chan CC
        Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents.
        Am J Ophthalmol. 1983; 96: 275-282
        • Hows JM
        • Smith JM
        • Baughan A
        • Gordon-Smith EL
        Nephrotoxicity in marrow graft recipients treated with cyclosporine.
        Transplant Proc. 1983; 15: 2708-2711
        • Flechner SM
        • Van Buren CT
        • Kahan BO
        Nephrotoxicity in renal recipients.
        Transplant Proc. 1983; 15: 2689-2694
        • Egel J
        • Greenberg A
        • Thompson M
        • et al.
        Renal failure (RF) in heart transplant patients receiving cyclosporine.
        Transplant Proc. 1983; 15: 2706-2707
        • Joss OV
        • Barrett AJ
        • Kendra JR
        • Lucas CF
        • Desai S
        Hypertension and convulsions in children receiving cyclosporin A.
        Lancet. 1982; II: 906
        • Atkinson K
        • Biggs JC
        • Dodds A
        • Concannon AJ
        Cyclosporin-associated hepatotoxicity after allogeneic marrow transplantation in man.
        Transplant Proc. 1983; 15: 2761-2767
        • Loertscher R
        • Wenk M
        • Harder F
        • Brunner F
        • Follath F
        • Thiel G
        Hyperbilirubinaemia and cyclosporin A levels in renal transplant patients.
        Lancet. 1981; II: 635-636
        • Rodger RSC
        • Turney JH
        • Haynes I
        • Michael J
        • Adu D
        • McMaster P
        Cyclosporine and liver function in renal allograft recipients.
        Transplant Proc. 1983; 15: 2754-2756
        • Thiru S
        • Calne RY
        • Nagington J
        Lymphoma in renal allograft patients treated with cyclosporin A as one of the immunosuppressive agents.
        Transplant Proc. 1981; 13: 359
        • Penn I
        Lymphomas complicating organ transplantation.
        Transplant Proc. 1983; 15: 2790-2797
        • Ho M
        • Wajszcuk CP
        • Hardy A
        • et al.
        Infections in kidney, heart and liver transplant recipients on cyclosporine.
        Transplant Proc. 1983; 15: 2768-2774
        • Dummer JS
        • Bahnson HT
        • Griffith BP
        • Hardesty RL
        • Thompson ME
        • Ho M
        Infections in patients on cyclosporine and prednisone following cardiac transplants.
        Transplant Proc. 1983; 15: 2779-2781
        • Hamilton DV
        • Evans DB
        • Thiru S
        Toxicity of cyclosporin A in organ grafting.
        in: White DJG Cyclosporin A. Elsevier Biomedical Press, Amsterdam, The Netherlands1982: 393-411
        • Laupacis A
        Complications of cyclosporine therapy—a comparison to azathioprine.
        Transplant Proc. 1983; 15: 2748-2754
        • Rolles K
        • Calne RY
        Two cases of benign lumps after treatment with cyclosporin A.
        Lancet. 1980; II: 795
        • Lever WF
        Histopathology of the skin.
        in: JB Lippincott, Philadelphia1975: 28